FY2025 EPS Estimates for NeuroPace Cut by Cantor Fitzgerald

NeuroPace, Inc. (NASDAQ:NPCE) – Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for NeuroPace in a note issued to investors on Wednesday, May 14th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of ($0.87) for the year, down from their previous forecast of ($0.54). Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $22.52 million for the quarter, compared to the consensus estimate of $21.85 million.

Other equities research analysts also recently issued research reports about the stock. Wells Fargo & Company raised their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, UBS Group started coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

NeuroPace Trading Up 2.4%

Shares of NPCE stock opened at $17.49 on Friday. The business’s 50 day moving average is $11.97 and its two-hundred day moving average is $11.59. The company has a market cap of $572.85 million, a PE ratio of -17.49 and a beta of 2.04. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. NeuroPace has a 12 month low of $5.45 and a 12 month high of $17.85.

Insiders Place Their Bets

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 168,136 shares of NeuroPace stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the transaction, the insider now directly owns 3,238,199 shares of the company’s stock, valued at approximately $51,325,454.15. The trade was a 4.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,517,315 shares of company stock worth $53,285,641 over the last 90 days. Corporate insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NPCE. Rhumbline Advisers raised its holdings in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock valued at $212,000 after buying an additional 2,267 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after buying an additional 2,279 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of NeuroPace in the fourth quarter valued at about $29,000. Charles Schwab Investment Management Inc. raised its holdings in shares of NeuroPace by 7.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company’s stock valued at $482,000 after buying an additional 2,700 shares during the last quarter. Finally, GAMMA Investing LLC bought a new position in shares of NeuroPace in the first quarter valued at about $53,000. 78.83% of the stock is owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.